The Poseidon study was a phase I/II study in second-line KRAS mild-type metastatic colorectal cancer (mCRC) that did not meet its endpoint of progression-free survival, but did suggest a subgroup of patients with high alpha v beta 6 integrin expression who would benefit from abituzumab. In this interview, Dr Rita Laeufle tells us about the retrospective analysis of the Poseidon study, whereby patients with left-sided KRAS wild-type mCRC and high expression of alpha v beta 6 showed improved overall survival and progression-free survival. Dr Laeufle explains how future research will start to focus on first-line therapy and how patients with other types of colon cancer can benefit from these results.
1. What was the background and rationale behind the retrospective explorative analysis of the Poseidon study? (0:11)
2. What were the key findings from the analysis? (2:49)
3. What are the next steps in this area of research over the coming years? (3:27)
4. How do you anticipate these findings will impact clinical practice in the future? (4:33)
Speaker disclosures: Rita Laeufle has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Colorectal Cancer
Jared Weiss, ESMO 2021: The Efficacy and Safety Findings of the KRYSTAL-1 Study
touchONCOLOGY joins Dr Jared Weiss (UNC Lineburger Comprehensive Cancer Care Center, Chapel Hill, NC, USA) at ESMO 2021 to discuss KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation. Questions 1. What is the rationale for targeting KRAS tumour mutations in colorectal cancer? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Hans Prenen, ASCO GI 2021: Updates from the alloSHRINK Study
It was a pleasure to talk to Hans Prenen about recent updates in CAR T cell therapy and the current findings from the alloSHRINK study (Clinical Trial Identifier: NCT03692429). The abstract ‘Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.’ (ABSTRACT NUMBER: 74) was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!